Agios Pharm
USUSDAgios Pharm (US:AGIO) — Biotechnology: Pharmaceutical Preparations. Количество бирж, на которых торгуются акции компании: 2. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О компании
- Сайт
- agios.com
- Взаимодействие с инвесторами
- investor.agios.com/
- Сектор
- Health Care · Biotechnology: Pharmaceutical Preparations
- Штаб-квартира
- Cambridge, United States
- Генеральный директор
- Brian M. Goff
- Сотрудники
- 539
- Основана
- 2008
- Акций в обращении
- 59.7 млн на 2026-07-24
- Свободное обращение
- 50.02 млн
- Рыночная капитализация
- 2 млрд USD
- Инсайдеры
- 1.07%
- Институциональные инвесторы
- 112.31%
- Отрасль (SIC)
- Pharmaceutical Preparations
- ISIN
- US00847X1046
- LEI
- 529900ONJHY8EOGYT555
- FCF
- −365 млн USD
- Долг
- 0
- Прибыль и FCF — за 12 месяцев до 30.06.2026 года (последний отчет компании).
Описание
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Новости этой недели
Новостей с сайта компании пока нет.
Крупнейшие держатели
| Держатель | Доля | Акции | Дата отчета |
|---|---|---|---|
| Blackrock Inc. | 10.81% | 6.46 млн | 2026-06-30 |
| Farallon Capital Managem… | 9.91% | 5.92 млн | 2026-06-30 |
| State Street Corporation | 5.92% | 3.53 млн | 2026-06-30 |
| Lynx1 Capital Management… | 5.71% | 3.41 млн | 2026-06-30 |
| Shaw D.E. & Co., Inc. | 5.2% | 3.11 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.85% | 2.9 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.49% | 2.68 млн | 2026-06-30 |
| Armistice Capital, LLC | 4.02% | 2.4 млн | 2026-06-30 |
| Erste Asset Management G… | 3.61% | 2.15 млн | 2026-06-30 |
| SPDR SERIES TRUST-State… | 3.54% | 2.11 млн | 2026-08-31 |
| Nomura Asset Management… | 3.54% | 2.11 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.16% | 1.89 млн | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.52% | 1.51 млн | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 2.28% | 1.36 млн | 2026-06-30 |
| Delaware Group Equity Fu… | 1.92% | 1.14 млн | 2026-05-31 |
| VANGUARD INDEX FUNDS-Van… | 1.32% | 788 655 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 683 990 | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.08% | 646 318 | 2026-07-31 |
| Fidelity Rutland Square… | 0.88% | 526 121 | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.86% | 511 994 | 2026-07-31 |
| FOUSE JACQUALYN A. (Dire… | ≈0.26% | 154 156 | 2026-06-18 |
| GHEUENS SARAH (Officer) | ≈0.09% | 54 645 | 2026-08-04 |
| SCADDEN DAVID T. (Direct… | ≈0.03% | 20 419 | 2026-06-18 |
| HO MAYKIN (Director) | ≈0.03% | 19 848 | 2026-06-18 |
| BALLAL RAHUL D. (Directo… | ≈0.03% | 15 230 | 2026-06-18 |
| SMITH CYNTHIA (Director) | ≈0.03% | 15 230 | 2026-06-18 |
| FOSTER-CHEEK KAYE I (Dir… | ≈0.02% | 12 484 | 2026-06-18 |
| ADAMS CATHERINE OWEN (Di… | ≈0.02% | 10 865 | 2026-06-18 |
| CAPELLO JEFFREY D (Direc… | ≈0.02% | 10 865 | 2026-06-18 |
| BACKSTROM JAY T (Directo… | ≈0% | 1 447 | 2026-07-08 |
